Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronickidneydisease CKD-EPI ChronicKidneyDisease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice ESKD End-stage kidneydisease HD Hemodialysis HR Hazard ratio KFRE Kidney Failure Risk Equation MD Mean Difference MDRD Modification of Diet in RenalDisease OR Odds Ratio (...) PD Peritoneal dialysis QoL Quality of life RCT Randomized controlled trial REIN Renal Epidemiology and Information Network RR Relative Risk RRT Renal replacement therapy SGA Subjective global assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronickidneydisease CKD-EPI ChronicKidneyDisease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP
. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronicrenal failure. Nefrologia. 2012;32:809-818. 2. Kanderian AS, Francis GS. Cardiac troponins and chronickidneydisease. Kidney Int. 2006;69:1112-1114. 3. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronickidneydisease without suspected acute coronary syndrome. Ann Intern Med.2014;161: 491-501. 4. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I (...) among asymptomatic patients with end-stage renaldisease: a meta-analysis. Circulation. 2005;112:3088-3096. 5. Amsterdam EZ, Wenger NK, Peterson ED, et al. 2014 AHA/ACC guideline for the management of patients with non-ST- elevation acute coronary syndromes.JAm Coll Cardiol. 2014;64:e139-228. 6. Acharji S, Baber U, Mehran R, et al. Prognostic signi?cance of elevated baseline troponin in patients with acute coronary syndromes and chronickidney Systematic Review Snapshot 108 Annals of Emergency
on Ethnicity, Culture and Health, School of Public Health, University of Michigan, Ann Arbor, MI, USA. eng R01 AG018418 AG NIA NIH HHS United States Editorial 2015 12 12 Iran J Nephropharmacol 101679372 2345-4202 Chronickidneydisease End stage renaldisease Health disparities Socio-economics 2015 10 07 2015 12 05 2017 2 16 6 0 2015 12 12 0 0 2015 12 12 0 1 epublish 28197489 PMC5297505 Am J Mens Health. 2013 Jul;7(4 Suppl):58S-67S 23609347 J Diabetes Complications. 2003 Jan-Feb;17(1):39-58 12505756 Clin J (...) Racial disparities in chronickidneydiseases in the United States; a pressing public health challenge with social, behavioral and medical causes 28197489 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Racial disparities in chronickidneydiseases in the United States; a pressing public health challenge with social, behavioral and medical causes. 4-6 Assari Shervin S Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA ; Center for Research
Endothelin 1 gene is not a major modifier of chronickidneydisease advancement among the autosomal dominant polycystic kidneydisease patients Introduction: Autosomal dominant polycystic kidneydisease (ADPKD) is characterized by the presence of numerous cysts in the kidney and manifest with various renal and extra-renal complications leading to ESRD. Endothelin may contribute to various renal and extra-renal manifestations pointing to genetic and environmental modifying factors that alter (...) the risk of developing chronickidneydisease (CKD) in ADPKD. In the present study we investigated six genes coding for endothelin 1 ( EDN1 ) tagging-single nucleotide polymorphisms (tag-SNPs) to unravel the EDN1 gene modifier effect for renaldisease progression in ADPKD. Materials and Methods: The tag-SNPs were genotyped using FRET-based KASPar method in 108 ADPKD patients and 119 healthy subjects. Cochran-Armitage trend test was used to determine the association between ADPKD and EDN1 tag-SNPs
Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronickidneydisease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD) Sonidegib (Odomzo ® ) capsule Novartis Pharmaceuticals UK Ltd November 2015 Advice context: The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication
A suPAR Biomarker for ChronicKidneyDisease. 26539740 2015 11 23 2018 12 02 1533-4406 373 20 2015 Nov 12 The New England journal of medicine N. Engl. J. Med. A suPAR Biomarker for ChronicKidneyDisease. 1971-2 10.1056/NEJMe1512997 Skorecki Karl L KL From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel (K.L.S.); and the Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC (...) (B.I.F.). Freedman Barry I BI eng Editorial Comment 2015 11 05 United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2015 11 6 6 0 2015 11 6 6 0 2015 12 15 6 0 ppublish 26539740 10.1056/NEJMe1512997
Soluble Urokinase Receptor and ChronicKidneyDisease. Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronickidney disease.We measured (...) plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronickidneydisease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox
chronickidneydisease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronickidneydisease. We discuss resistant (...) The double challenge of resistant hypertension and chronickidneydisease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronickidneydisease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronickidneydisease, while
Evaluation of Rhubarb Supplementation in Stages 3 and 4 of ChronicKidneyDisease: A Randomized Clinical Trial. Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronickidneydisease. Material and Methods. This study was a prospective comparative study conducted in patients of chronickidneydisease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two (...) management in stage 3 and stage 4 patients of chronickidneydisease.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronickidneydisease (the C-SURFER study): a combination phase 3 study. Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronickidneydisease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronickidneydisease have few treatment options. This study assesses an all-oral, ribavirin-free regimen (...) in patients with HCV genotype 1 infection and stage 4-5 chronickidney disease.In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronickidneydisease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done
2015LancetControlled trial quality: predicted high
A Positive Association Between Periodontal Disease and ChronicKidneyDisease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and ChronicKidneyDisease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronickidneydisease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronickidneydisease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen
with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronickidneydisease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronickidneydisease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary (...) risk of cardiovascular events, acute kidney injury, falls, frailty and mortality. Table 1: Prevalence of ChronicKidneyDisease Stage Description eGFR (mL/min/1.73m 2 ) Population Prevalence 1 CKD with normal GFR + other kidney damage >90 3.3% 2 Mild CKD and other kidney damage 60-89 3.0% 3a 3b Mild to Moderate CKD Moderate to Severe CKD 45-59 30-44 4.3% 4 Severe CKD 15-29 0.2% 5 Established renal failure 30mg/mmol (macro-albuminuria often dipstick proteinuria) ? GFR in healthy young adults
equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation selection would impact drug-dosing recommendations.Estimated GFR (eGFR) was calculated with the Cockcroft-Gault, Modification of Diet in RenalDisease Study (MDRD), and ChronicKidneyDisease Epidemiology Collaboration (CKD-EPI) equations for 128,805 patients undergoing PCI in the state of Michigan. Agreement between patient pre-PCI eGFR estimates and resultant CKD stage classifications (...) Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With ChronicKidneyDisease Undergoing Percutaneous Coronary Interventions Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronickidneydisease (CKD) undergoing percutaneous coronary intervention (PCI).The goals of this study were to identify which
Chronickidneydisease. This issue provides a clinical overview of chronickidneydisease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration
. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Erythropoiesis Stimulating Agents in ChronicKidneyDisease (...) of vascular access thrombosis and stroke. No impacts of higher Hb targets were observed on end-stage renaldisease or all-cause mortality. 2 The identified randomized controlled trial 3 examined the effects of maintaining high Hb on renal function in patients with CKD who were not on dialysis. Patients were randomized to either a Erythropoiesis Stimulating Agents in ChronicKidneyDisease 3 high Hb group (Hb equal to 11.0 g/dL through 13.0 g/dL) receiving darbepoetin alfa or a low Hb group (Hb equal
, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dialysis in Stage 5 ChronicKidneyDisease: Clinical Effectiveness and Guidelines DATE (...) estimated GFRs was statistically significantly associated with increased risk of mortality; however, significant study heterogeneity was also noted. Dialysis in Stage 5 ChronicKidneyDisease 3 REFERENCES SUMMARIZED Health Technology Assessments No literature identified Systematic Reviews and Meta-analyses 1. O'Connor NR, Kumar P. Conservative management of end-stage renaldisease without dialysis: a systematic review. J Palliat Med [Internet]. 2012 Feb [cited 2015 Mar 13];15(2):228-35. Available from
Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, ChronicKidneyDisease, or Heart Failure Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) -Inflammatory Drugs in Patients with Hypertension, ChronicKidneyDisease, or Heart Failure: Benefits, Harms, and Guidelines DATE: 10 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of using non-steroidal anti-inflammatory drugs (NSAIDS) in patients with hypertension, chronickidneydisease, or heart failure? 2. What are the evidence-based guidelines for using NSAIDS in patients with hypertension, chronickidneydisease, or heart failure? KEY FINDINGS One systematic review, one